Kirkland – Pfizer is proud to announce that ABRILADA™ (adalimumab), a biosimilar to the reference biologic drug Humira1 (adalimumab), is now available in Canada for the treatment of certain patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease (in people aged 13 and older), ulcerative colitis, plaque psoriasis, uveitis (in adults and children) and hidradenitis suppurativa (in people aged 12 and older)2.
“We believe biosimilars like ABRILADA play a key role in creating a more sustainable health care system, representing an opportunity to help improve access to important treatment options for patients living with chronic, and often debilitating, inflammatory conditions,” said Frédéric Lavoie, Canada Lead, Pfizer Inflammation and Immunology. “Our current portfolio of approved biosimilar products is one of the broadest in the industry and we are proud to offer additional treatment options for patients.”
The Health Canada approval was based on the review of a comprehensive data package, which demonstrated biosimilarity of ABRILADA to the reference biologic drug Humira. This includes results from the REFLECTIONS B538-02 clinical comparative study, which evaluated the efficacy, safety and immunogenicity of ABRILADA.3